Evidence map›Paper›PMID 24424397›Full record

ArticleInternational journal of molecular medicine2014

Human single-chain variable fragment antibody inhibits macrophage migration inhibitory factor tautomerase activity.

Mayuri Tarasuk, Ornnuthchar Poungpair, Duangporn Ungsupravate, Kunan Bangphoomi, Wanpen Chaicumpa, Pa-Thai Yenchitsomanus

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mayuri TarasukDivision of Molecular Medicine, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Ornnuthchar PoungpairDivision of Molecular Medicine, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Duangporn UngsupravateDivision of Molecular Medicine, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Kunan BangphoomiDepartment of Biochemistry, Faculty of Sciences, Kasetsart University, Bangkok, Thailand.
Wanpen ChaicumpaLaboratory for Research and Technology Development, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Pa-Thai YenchitsomanusDivision of Molecular Medicine, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Mahidol University · THSiriraj Hospital · THKasetsart University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine, secreted from a variety of immune cells, that regulates innate and adaptive immune responses. Elevation of MIF levels in plasma correlates with the severity of inflammatory diseases in humans. Inhibition of MIF or its tautomerase activity ameliorates disease severity by reducing inflammatory responses. In this study, the human single-chain variable fragment (HuScFv) antibody specific to MIF was selected from the human antibody phage display library by using purified recombinant full-length human MIF (rMIF) as the target antigen. Monoclonal HuScFv was produced from phage-transformed bacteria and tested for their binding activities to rMIF by indirect enzyme-linked immunosorbent assay as well as to native MIF by western blot analysis and immunofluorescence assay. The HuScFv with highest binding signal to rMIF also inhibited the tautomerase activities of both rMIF and native MIF in human monoblastic leukemia (U937) cells in a dose-dependent manner. Mimotope searching and molecular docking concordantly demonstrated that the HuScFv interacted with Lys32 and Ile64 in the MIF tautomerase active site. To the best of our knowledge, this is the first study to focus on MIF-specific fully-human antibody fragment with a tautomerase-inhibitory effect that has potential to be developed as anti-inflammatory biomolecules for human use.

Indexed as

Immunity, InnateAnti-Inflammatory AgentsCatalytic DomainCell Line, TumorEnzyme-Linked Immunosorbent AssayHumansIntramolecular OxidoreductasesLeukemiaMacrophage Migration-Inhibitory FactorsProtein BindingSingle-Chain AntibodiesAnti-Inflammatory AgentsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, humanSingle-Chain Antibodies

Identifiers

PMID24424397
PMCPMC3926510
OpenAlexW1973561182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.